RE:RE:Big pharma is set to keep signing bigger deals in 2024McKinsey & Company's Vision 2028 on China commented that: "Chinese biopharmas’ emphasis on mature MoAs reflects their generally risk-averse approach to clinical development. It has also often left China-originated biopharmas in crowded therapeutic areas, limiting their ability to have an impact on patients’ lives. In the future, companies should pay much more attention to unmet medical needs. This could take many different forms—for instance, targeting a novel mechanism or adopting a differentiated development strategy. Clinical differentiation backed by robust data is essential to securing sustainable advantage."
Perhaps the Chinese will be moving on the acquisition of ONCY to address the all of the Chinese deficiencies that McKinsey identified in their report.